Eli Lilly and Company (LLY) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Eli Lilly And Company.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.062 Thank you for holding. We look forward to talking with you soon. 00:00:04.062 -- 00:00:07.968 Please hold the line and we'll be right back with you. 00:00:13.784 -- 00:00:18.971 Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q1 2025 earnings 00:00:18.971 -- 00:00:22.856 conference call. At this time, all participants are on a listen-only mode. 00:00:22.856 -- 00:00:26.782 Later, we will be conducting a question and answer session and instructions will be given 00:00:26.782 -- 00:00:31.087 at that time. Should you require assistance during the call, please press star, then 00:00:31.087 -- 00:00:33.991 zero, and an operator will assist you offline. 00:00:33.991 -- 00:00:38.197 I would now like to turn the conference over to your host, Mike Zappar, Senior Vice President 00:00:38.197 -- 00:00:41.899 of Investor Relations. Please go ahead. 00:00:42.102 -- 00:00:46.062 Good morning. Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2025 00:00:46.062 -- 00:00:51.070 earnings call. I'm Mike Spahr, Senior Vice President of Investor Relations. 00:00:51.070 -- 00:00:56.098 Joining me on today's call are Dave Ricks, Lilly's Chair and CEO, Lucas Montarse, Chief 00:00:56.098 -- 00:01:01.527 Financial Officer, Dr. Dan Skowronski, Chief Scientific Officer and President of Lilly 00:01:01.527 -- 00:01:02.929 Immunology, 00:01:02.929 -- 00:01:07.656 Anne White, President of Lilly Neuroscience, David Hufa, President of Lilly International, 00:01:07.656 -- 00:01:11.835 Jake Van Narden, President of Lilly Oncology, and Patrick Johnson, President of Cardio 00:01:11.835 -- 00:01:17.021 Metabolic Health and Lilly USA. We're also joined by Mark Kuhman, Wes Tall, and Wai Wong 00:01:17.021 -- 00:01:19.344 of the I...